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Abstract
Background: Ultrasound guided fine needle aspiration (USFNA) biopsies of thyroid nodules sometimes create a
decision-making dilemma for surgeons as they may yield falsely benign results. The McGill Thyroid Nodule
Score + (MTNS+) was developed to aid in clinical guidance regarding the management of patients with these
USFNA results. The aim of this study was to assess the MTNS+ as a clinical tool in patients with benign preoperative
thyroid nodule USFNAs and to analyze the relationship between nodule size and malignancy in these patients.
Methods: We conducted a retrospective chart review of 1312 patients who underwent thyroidectomies between
2010 and 2015 at the McGill University Teaching Hospitals. Patients with Bethesda II (benign) USFNA results, calculated
MTNS+, and nodule size evaluated on ultrasound were included in the study. The false-negative rate was calculated,
and MTNS+ and nodule size were each compared to final pathology results. Binary logistic regression was used for
statistical analysis.
Results: Of the 1312 patients, 101 met the inclusion criteria and together had an average MTNS+ score of 6.83, which
corresponds to a predicted malignancy rate between 25 and 33 %. Final pathology revealed malignancy in 16 (15.8 %)
subjects. The average MTNS+ of patients with malignant nodules on surgical pathology was 8.25, while that of patients
with benign nodules was 6.56.
Patients with nodule size 1–1.9 cm (a) and 2–2.9 cm (b) each had an equal rate of malignancy of 2.97 % (n = 3), nodule
size 3–3.9 cm (c) had a rate of 1.98 % (n = 2), and nodule size ≥4 cm (d) a rate of 7.92 % (n = 8).
Conclusion: The rate of malignancy (15.8 %) is higher than expected when reviewing the risk of malignancy in nodules
considered as Bethesda class 2. On the other hand, the rate is lower than the 25–33 % predicted by the MTNS+. We also
found a higher malignancy rate for nodules above 4 cm in size, but size was a poor predictor of malignancy when used
alone. Therefore, while the MTNS+ may be helpful at helping to identify USFNAs that are incorrectly classified as benign,
the percentage risk of malignancy is lower than expected.
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Background
The incidence of thyroid cancer has been significantly and
rapidly increasing in Canada over the past 30 years [1, 2].
Ultrasound-guided fine needle aspiration (USFNA) bi-
opsy is currently considered the gold standard for the
assessment and management of thyroid nodules.
While it is undeniable that USFNAs provide very im-
portant information as to the nature of the nodule,
they may yield a falsely benign result in 5 % of cases [3, 4].
Given the potential health implications of misclassifying
malignant thyroid nodules as benign, it is necessary to
find a complementary clinical tool to evaluate the risk
of malignancy and properly select patients who require
surgery.
Previous studies [1, 5, 6] advocate the McGill Thyroid
Nodule Score + (MTNS+), as a valuable scoring-system
used to accurately determine a patient’s overall risk of ma-
lignancy. The MTNS+ is based on 23 known thyroid
cancer risk factors, which are tabulated and then assigned
a percentage risk of malignancy (Table 1) [6].
Table 1 McGill Thyroid Nodule Score Plus (MTNS+) Scoring Template
TSH Thyroid stimulating hormone. Tg Thyroglobulin. PET Positron emission tomography
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This study aims to assess the accuracy of the MTNS+ in
predicting the risk of malignancy of thyroid nodules with
benign USFNAs. The association between nodule size and
malignancy rate is also evaluated. Findings could reduce
the proportion of missed malignancies and improve man-
agement of patients with thyroid nodules.
Methods
Multi-center ethics review approval was obtained from Re-
search Ethics Committees at the Jewish General Hospital
(JGH) and the McGill University Health Centre (MUHC).
We conducted a retrospective chart review of 1312 pa-
tients who underwent thyroidectomies at the McGill
University Teaching Hospitals between January 2010
and March 2015. 101 patients (7.7 %) met inclusion cri-
teria that consisted of having Bethesda II (benign)
USFNA biopsy results, pre-operative calculated MTNS+
scores and recorded nodule size on ultrasound. We ex-
cluded patients with unavailable pre-operative MTNS+,
USFNA and nodule size results. All USFNA samples
were obtained by endocrinologists, thyroid surgeons, or
radiologists. Collected information on the MTNS+ was
based on a scoring sheet that has been regularly filled
out over many years when a patient consults the doctor.
Positron emission tomography (PET) scan and BRAF
mutation are the two MTNS+ variables that are not rou-
tinely measured.
MTNS+ and thyroid nodule size on ultrasound were
each compared to final post-operative pathology classi-
fied as either benign or malignant. Papillary microcar-
cinomas with extrathyroidal extension (ETE) were
considered malignant due to their unpredictable ag-
gressive behaviour when associated with ETE [6, 7]. All
other papillary microcarcinomas were considered be-
nign, as they usually progress indolently [6, 7]. Using
USFNA allowed us to ensure malignancy was assigned
to the ipsilateral nodule that was biopsied, thus avoid-
ing falsely assigning malignancy to benign nodules in
patients with multinodular thyroid glands. The malig-
nancy rate, the mean MTNS+, and the standard devia-
tions were calculated for the group of patients with
Bethesda II cytology, as well as within each subgroup:
malignant and benign on surgical pathology results.
Statistical analysis was done using Binary Logistic Re-
gression for MTNS+ when compared to malignancy
rates. Nodule size was separated into four categories:
a) 1–1.9 cm, b) 2–2.9 cm, c) 3–3.9 cm, and d) ≥4 cm.
Malignancy rates were calculated for each category
and a receiver operating characteristic (ROC) curve
was also computed for malignancy and nodule size as a
continuous variable. Bivariate regression analysis and
Spearman’s correlations were run to compare MTNS+
and nodule size.
Results
Of the 1312 charts reviewed, 101 patients (7.7 %) met
inclusion criteria. Patient age ranged from 23 to 85, with
a mean of 52 years old. There was a 6-fold female pre-
dominance with a male to female ratio of 14:87. Final
pathology revealed malignancy in 16 subjects (15.8 %),
while 85 (84.2 %) were benign. One of the 16 patients in-
cluded in the malignant group had a microcarcinoma
with ETE on final pathology. In this selected patient
population, MTNS+ scores ranged from 1 to 18, with a
mean value and standard deviation (SD) of 6.83 ± 2.31.
MTNS+ and malignancy
Benign and malignant rates and densities for each MTNS+
are presented in Table 2 and Fig. 1, respectively. Amongst
the 101 patients included in the study, all malignant
nodules had an MTNS+ equal to or above 5, while be-
nign nodules had MTNS+ values as low as 1. Average
MTNS+ of patients with malignant pathology (8.25 ±
2.86 [95 % CI 6.72, 9.78]) was higher than MTNS+ of
patients in the benign group (6.56 ± 2.11 [95 % CI 6.11,
7.02]) (Table 3). The MTNS+ mean difference between
malignant and benign groups was 1.69 with 95 % confi-
dence interval (CI) [0.11, 3.26].
Table 2 Distribution of benign USFNA MTNS+ scores and their
associated surgical pathology diagnosis
MTNS Total (n) Benign n (%) Malignant n (%)
1 1 1 (1.0) 0 (0.0)
2 1 1 (1.0) 0 (0.0)
3 0 0 (0.0) 0 (0.0)
4 9 9 (8.9) 0 (0.0)
5 21 20 (19.8) 1 (1.0)
6 14 13 (12.9) 1 (1.0)
7 20 15 (14.9) 5 (5.0)
8 17 12 (11.9) 5 (5.0)
9 7 5 (5.0) 2 (2.0)
10 7 6 (5.9) 1 (1.0)
11 2 2 (2.0) 0 (0.0)
12 0 0 (0.0) 0 (0.0)
13 1 1 (1.0) 0 (0.0)
14 0 0 (0.0) 0 (0.0)
15 0 0 (0.0) 0 (0.0)
16 0 0 (0.0) 0 (0.0)
17 0 0 (0.0) 0 (0.0)
18 1 0 (0.0) 1 (1.0)
Total 101 85 (84.2) 16 (15.8)
MTNS+ McGill Thyroid Nodule Score Plus. USFNA Ultrasound guided fine
needle aspiration
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A positive association between MTNS+ and malig-
nancy was confirmed by logistic regression analysis with
an odds ratio of 1.34 [95 % CI 1.05, 1.71].
MTNS+ and nodule size
Largest nodule size on ultrasound ranged between 1
and 8.9 cm with a mean and standard deviation of
4.13 cm ±1.53. A positive correlation between MTNS+
and nodule size was shown by Spearman’s correlation
with an “r” coefficient value of 0.146 [95 % CI -0.05,
0.33]. The MTNS+ odds ratio was 1.52 [95 % CI 1.130,
2.044] when adjusted for nodule size through bivariate
regression analysis. Patients with nodule size 1–1.9 cm
had an OR of 16.2 [95 % CI 1.83, 143.427], those with
nodule size 2–2.9 cm had an OR of 4.387 [95 % CI
0.806, 23.876], and nodule size 3–3.9 cm an OR of
0.341 [95 % CI 0.063, 1.832] when compared to nodules
above 4 cm in size.
Nodule size and malignancy
Benign and malignancy rates according to nodule size
categories (cm) are presented in Table 4. Average nodule
size was similar in patients with malignant and benign
pathology (3.67 cm ±1.60, and 4.23 cm ±1.51, respectively).
Patients with nodule size 1–1.9 cm (a) had a rate of malig-
nancy of 2.97 % (n = 3), nodule size 2-2.9 cm (b) a rate of
2.97 % (n = 3), nodule size 3–3.9 cm (c) a rate of 1.98 %
(n = 2), and nodule size ≥4 cm (d) a malignancy rate of
7.92 % (n = 8) (Fig. 2). ROC curve for nodule size and
malignancy rate is presented in Fig. 3.
Fig. 1 Frequency distribution of pre-operative MTNS+ in 101 thyroidectomy patients with Bethesda II USFNAs. Distribution of MTNS+ scores are
displayed for thyroid nodules with: Top) Benign pathology on surgical biopsy, Bottom) Malignant pathology on surgical biopsy. MTNS+: McGill
Thyroid Nodule Score Plus. USFNA: Ultrasound guided fine needle aspiration
Table 3 Distribution of MTNS+ scores within benign and
malignant thyroid nodule categories confirmed on surgical
pathology
Bethesda II Thyroid Nodules (N = 101)
Benign (84.2 %) Malignant (15.8 %)
N Mean StdDev Min Max N Mean StdDev Min Max
MTNS 85 6.56 2.11 1 13 16 8.25 2.86 5 18
MTNS+ McGill Thyroid Nodule Score Plus. StdDev standard deviation
Table 4 Association of benign USFNA nodule size and their
corresponding surgical pathology diagnosis
Nodule Size (cm) Total n (%) Benign n (%) Malignant n (%)
a) 1–1.9 6 (5.94) 3 (2.97) 3 (2.97)
b) 2–2.9 9 (8.91) 6 (5.94) 3 (2.97)
c) 3–3.9 36 (35.64) 34 (33.66) 2 (1.98)
d) ≥4 50 (49.50) 42 (41.58) 8 (7.92)
Total 101 (100) 85 (84.16) 16 (15.84)
Nodule sizes were determined pre-operatively by ultrasound and were subdivided
into categories a) 1–1.9 cm, b) 2–2.9 cm, c) 3–3.9 cm, d) ≥4 cm
USFNA Ultrasound guided fine needle aspiration
Khalife et al. Journal of Otolaryngology - Head and Neck Surgery  (2016) 45:29 Page 4 of 7
Discussion
Approximately 60 % of all performed USFNAs are
Bethesda II (benign) on cytology [8] and should ideally
result in a relief for patients, surgeons, and clinicians,
in terms of treatment and prognosis. However, the 5 %
false-negative rate of benign USFNAs [3, 9] cannot be
disregarded. This is why the American Thyroid Asso-
ciation (ATA), the American Association of Clinical
Endocrinologists (AACE) and the European Thyroid
Association (ETA) suggest close observation of pa-
tients with follow-up ultrasounds 6–18 months later,
and repeat USFNA if nodule growth is seen [3, 10].
Fig. 2 Association between thyroid nodule size and surgical pathology diagnosis in patients with benign USFNA biopsies. Nodule sizes on pre-operative
ultrasounds were subdivided into categories a) 1–1.9 cm, b) 2–2.9 cm, c) 3–3.9 cm, d) ≥4 cm. USFNA: Ultrasound guided fine needle aspiration
Fig. 3 Receiver operating characteristic curve for thyroid nodule size and risk of malignancy. Nodule size was determined by pre-operative ultrasound
and malignancy was confirmed by post-operative pathology
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Despite these recommendations, researchers con-
tinue to challenge the falsely benign rate stated by the
Bethesda Classification [2, 9–11]. The 15.8 % rate of
malignancy identified in our specific series is substan-
tially higher than that predicted by Bethesda and ATA
guidelines for benign USFNAs. Yet, it is consistent
with the higher rates reported throughout literature,
reaching values as high as 24.2 % [2, 5, 10–12]. This
wide range may be explained in part by variations in
technique, expertise and subjective interpreting differ-
ences between pathologists reading the slides and physi-
cians performing ultrasounds and USFNAs in different
institutions. Nevertheless, the difference remains signifi-
cant. With this scientific scepticism, benign USFNA re-
sults will continue to pose a dilemma for the thyroid
surgeon, particularly when known risk factors such as
suspicious ultrasound findings or exposure to ionizing
radiation are present.
Several studies recommend considering both cytology
and suspicious ultrasound findings before making treat-
ment decisions [10, 12]. Interestingly, Chernyavsky et al.
found that a remarkable 90 % of falsely benign USFNAs
(10.2 %) in their series had suspicious characteristics on
ultrasound [10]. They go on to suggest repeat USFNA
in these cases, in support of several other publications
[10, 12, 13].
This is the reason that an evidence-based scoring
system such as the MTNS+ assists in the pre-operative
assessment of thyroid nodules. Its use could allow for
earlier therapeutic decision-making. The MTNS+ has
been shown to be an accurate tool for predicting the risk
of malignancy [1, 6]. This 23-parameter summative tool
(Table 1) proposed by Sands et al. and then modified in
2013 by Scheffler et al., was developed in order to help
physicians formulate the management of thyroid nodules
[1, 6]. It takes into consideration multiple evidence-based
risk factors such as clinical factors (family history, expos-
ure to radiation), worrisome ultrasound features, as well
as cytology results. Combined into a single score, they en-
able a comprehensive identification of thyroid nodules
that are more likely to harbour a malignant disease.
Our study succeeds in demonstrating that the MTNS+
can be helpful in patients with benign USFNAs, but not
as precise as when assessing indeterminate nodules. The
101 patients with benign USFNA in our study had a
mean MTNS+ of 6.83 (±2.31), a value that predicts a risk
of malignancy between 25 and 33 % (Table 1). Although
this predicted range overestimates the true 15.8 % rate
found in our study (Tables 2 and 3), both values, in sup-
port of recent studies, prove to be significantly higher than
the 0–5 % stated by the ATA guidelines and the Bethesda
classification [3, 9]. This leads to the question of whether
an additional USFNA parameter in which points are
subtracted for patients with Bethesda II USFNA results
should be added to the MTNS+ in order to improve its
accuracy. New studies are currently underway to answer
this question.
With a statistically significant MTNS+ mean difference
between malignant and benign nodules, it is clear that
malignant nodules tend to have a higher MTNS+ score
than benign nodules. In addition, the odds ratio of 1.34
suggests that for every increase in 1 point of MTNS+,
there is an increase of 34 % in odds of malignancy for
this patient population. When adjusted for nodule size
in our bivariate regression analysis, the odds ratio for
MTNS+ increases to 1.52 and remains statistically
significant.
Williams et al., one of the only other Canadian-based
studies, had also reported a falsely benign rate of 16 %
[2]. Our equal malignancy rate supports their recom-
mendation that physicians should consider the malig-
nancy rate for the particular patient population being
treated rather than solely relying on generalized litera-
ture values based on cytology [2]. At our institution it
is uncommon for patients with benign USFNA’s to
undergo surgery. Only patients with a high index of
suspicion using the MTNS+ had surgery and were in-
cluded in this analysis. More specifically, this group of
patients had either worrisome ultrasound characteris-
tics or risk factors for thyroid cancer that were a cause
for concern. The MTNS+ scoring system automatically
calculates these variables and enables informed and
improved communication with patients. Therefore, the
decision was made to operate despite the USFNA re-
sults. Other factors that may have contributed in cer-
tain cases are the presence of anxiety, compressive
symptoms, or if the patient feels that the risk is too
high to leave the nodule there. As a result, the true
malignancy rate of patients who did not undergo sur-
gery remains unknown. Therefore, our study does not
contradict the commonly quoted 0–3 % malignancy
rate of benign USFNAs stated by the Bethesda Classifica-
tion [9]. In addition, the selection bias when selecting thy-
roidectomy patients is inevitable in surgical studies. It may
also differ from one institution to another since there is
still no consensus and no universal algorithm used to in-
crease suspicion index for patients with benign USFNAs.
Large nodule size has long been proposed as a risk fac-
tor for malignancy of thyroid nodules. This holds true
for patients with benign USFNAs, as previous findings
have shown falsely benign rates ranging from 10.4 to
17 % [14–17] in nodules larger than 3 or 4 cm, de-
pending on the study. Our study only supports these
findings for nodules above 4 cm in size, although the
malignancy rate of 7.92 % was slightly lower than that
found in other studies. Only 1.98 % of nodules between
3 and 3.9 cm were malignant, which is lower than that
of smaller and larger nodules (Fig. 2). This could be
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explained by the small number of patients in each nod-
ule size category. However, with a weak ROC curve
(Fig. 3), and since 44.58 % of nodules were above 4 cm
and benign on final pathology (Fig. 2), it is clear that
nodule size is a poor predictor of malignancy when
used alone for patients with benign USFNAs.
The major limitation of this study is the selection bias.
All patients underwent thyroidectomy based on higher
clinical suspicion of malignancy using the MTNS+. This
leaves the true malignancy rate unknown for patients
who did not undergo surgery. Unfortunately, this is the
case for research involving surgical patients.
Conclusion
With the uncertain malignancy rate of benign USFNAs,
the multitude of possible risk factors and the presence of a
spectrum of management alternatives (observation alone,
to re-biopsy and even thyroidectomy), the ensuing discus-
sion with the patient is often confusing, and leads to fur-
ther anxiety. MTNS+ appeases this problem as it allows
the physician to describe the risk of malignancy to the pa-
tient as an individualized percentage, thus simplifying
communication [1]. While MTNS+ in patients with be-
nign USFNAs plays a role in determining the management
in patients with benign thyroid nodules, it is less powerful
than USFNAs with indeterminate nodules.
Abbreviations
USFNA: ultrasound guided fine needle aspiration; MTNS+: McGill Thyroid
Nodule Score +; JGH: Jewish General Hospital; MUHC: McGill University
Health Centre; ETE: extrathyroidal extension; ATA: American Thyroid
Association; AACE: American Association of Clinical Endocrinologists;
ETA: European Thyroid Association; PET: positron emission tomography.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RP proposed the research topic and designed the study. SK reviewed the
charts, completed the database, and performed initial data interpretation. These
were revised by SB. SK authored the initial manuscript, which was subsequently
reviewed and approved by SK, SB, RP, VF, MH, MT, LR. Result interpretation and
important modifications were made by all authors to enable completion of this
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We would like to acknowledge Dr. Lawrence Joseph for completing the
statistical analyses of this study.
Financial support/disclosures
Funding from the BioMed Central Membership of Canadian Society of
Otolaryngology – Head and Neck Surgery.
Author details
1Department of Otolaryngology-Head and Neck Surgery, McGill University
Health Centre, 1001 Boulevard Decarie, Montreal, QC, Canada. 2Department
of Otolaryngology-Head and Neck Surgery, Sir Mortimer B. Davis-Jewish
General Hospital, McGill University, 3755 Côte Ste-Catherine Road, Montreal,
QC, Canada. 3Department of Pathology, Sir Mortimer B. Davis-Jewish General
Hospital, McGill University, 3755 Côte Ste-Catherine Road, Montreal, QC,
Canada. 4Department of Endocrinology and Metabolism, Sir Mortimer B.
Davis-Jewish General Hospital, McGill University, 3755 Côte Ste-Catherine
Road, Montreal, QC, Canada.
Received: 31 October 2015 Accepted: 25 April 2016
References
1. Sands NB, Karls S, Amir A, Tamilia M, Gologan O, Rochon L, et al. McGill
Thyroid Nodule Score (MTNS): “rating the risk,” a novel predictive scheme
for cancer risk determination. J Otolaryngol Head Neck Surg. 2011;40
Suppl 1:S1–13. Pubmed Abstract.
2. Williams BA, Bullock MJ, Trites JR, Taylor SM, Hart RD. Rates of thyroid
malignancy by FNA diagnostic category. J Otolaryngol Head Neck Surg.
2013;42:61. doi:10.1186/1916-0216-42-61. PubMed Abstract | Publisher
Full Text.
3. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al.
Revised American thyroid association management guidelines for patients
with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):
1167–214. doi:10.1089/thy.2009.0110. Publisher Full Text.
4. Alexander EK, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, et
al. Assessment of nondiagnostic ultrasound-guided fine needle aspirations
of thyroid nodules. J Clin Endocrinol Metab. 2002;87(11):4924–7. doi:10.
1210/jc.2002-020865. PubMed Abstract | Publisher Full Text.
5. Varshney R, Forest VI, Mascarella MA, Zawawi F, Rochon L, Hier MP, et al.
The Mcgill thyroid nodule score - does it help with indeterminate thyroid
nodules? J Otolaryngol Head Neck Surg. 2015;44:2. doi:10.1186/s40463-015-
0058-6. PubMed Abstract | Publisher Full Text.
6. Scheffler P, Forest VI, Leboeuf R, Florea AV, Tamilia M, Sands NB, et al. Serum
thyroglobulin improves the sensitivity of the McGill Thyroid Nodule Score
for well-differentiated thyroid cancer. Thyroid. 2014;24(5):852–7.
doi:10.1089/thy.2013.0191. PubMed Abstract | Publisher Full Text.
7. Ardito G, Revelli L, Giustozzi E, Salvatori M, Fadda G, Ardito F, et al.
Aggressive papillary thyroid microcarcinoma: prognostic factors and
therapeutic strategy. Clin Nucl Med. 2013;38(1):25–8. doi:10.1097/RLU.
0b013e318279bc65. PubMed Abstract | Publisher Full Text.
8. Ajmal S, Rapoport S, Ramirez Batlle H, Mazzaglia PJ. The natural history of
the benign thyroid nodule: what is the appropriate follow-up strategy?
J Am Coll Surg. 2015;220(6):987–92. doi:10.1016/j.jamcollsurg.2014.12.010.
PubMed Abstract | Publisher Full Text.
9. Cibas ES, Ali SZ, Conference NCITFSotS. The Bethesda system for reporting
thyroid cytopathology. Am J Clin Pathol. 2009;132(5):658–65.
doi:10.1309/AJCPPHLWMI3JV4LA. PubMed Abstract | Publisher Full Text.
10. Chernyavsky VS, Shanker BA, Davidov T, Crystal JS, Eng O, Ibrahim K, et al. Is one
benign fine needle aspiration enough? Ann Surg Oncol. 2012;19(5):1472–6. doi:
10.1245/s10434-011-2079-3. PubMed Abstract | Publisher Full Text.
11. Deniwar A, Hambleton C, Thethi T, Moroz K, Kandil E. Examining the
Bethesda criteria risk stratification of thyroid nodules. Pathol Res Pract.
2015;211(5):345–8. doi:10.1016/j.prp.2015.02.005. PubMed Abstract |
Publisher Full Text.
12. Choi YJ, Jung I, Min SJ, Kim HJ, Kim JH, Kim S, et al. Thyroid nodule with
benign cytology: is clinical follow-up enough? PLoS One. 2013;8(5),
e63834. doi:10.1371/journal.pone.0063834. PubMed Abstract | Publisher
Full Text.
13. Moon HJ, Kim EK, Kwak JY. Malignancy risk stratification in thyroid
nodules with benign results on cytology: combination of thyroid imaging
reporting and data system and Bethesda system. Ann Surg Oncol. 2014;
21(6):1898–903. doi:10.1245/s10434-014-3556-2. PubMed Abstract |
Publisher Full Text.
14. McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty SE, Yim JH. The
incidence of cancer and rate of false-negative cytology in thyroid nodules
greater than or equal to 4 cm in size. Surgery. 2007;142(6):837–44. doi:10.
1016/j.surg.2007.08.012. discussion 44 e1-3. PubMed Abstract | Publisher
Full Text.
15. Wharry LI, McCoy KL, Stang MT, Armstrong MJ, LeBeau SO, Tublin ME, et al.
Thyroid nodules (>/=4 cm): can ultrasound and cytology reliably exclude
cancer? World J Surg. 2014;38(3):614–21. doi:10.1007/s00268-013-2261-9.
PubMed Abstract | Publisher Full Text.
16. Giles WH, Maclellan RA, Gawande AA, Ruan DT, Alexander EK, Moore Jr FD,
et al. False negative cytology in large thyroid nodules. Ann Surg Oncol.
2015;22(1):152–7. doi:10.1245/s10434-014-3952-7. PubMed Abstract |
Publisher Full Text.
17. Meko JB, Norton JA. Large cystic/solid thyroid nodules: a potential false-
negative fine-needle aspiration. Surgery. 1995;118(6):996–1003. discussion -4.
PubMed Abstract | Publisher Full Text.
Khalife et al. Journal of Otolaryngology - Head and Neck Surgery  (2016) 45:29 Page 7 of 7
